Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04554992 · ClinicalTrials.gov registry record · Phase 1
Convalescent Plasma for the Treatment of COVID-19 (Coronavirus Disease 2019)
A Phase 1 study, sponsored by The Methodist Hospital Research Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 350
- Enrollment target
NCT04554992: Completed Phase 1 study, sponsored by The Methodist Hospital Research Institute.
NCT04554992 is a Phase 1 study that has completed, run by The Methodist Hospital Research Institute. The registered enrollment target is 350 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (483% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04554992, a Phase 1 study, has completed, sponsored by The Methodist Hospital Research Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 350 participants
- Enrollment target
Study Summary
This pilot, prospective study will assess the safety and efficacy of COVID-19 convalescent plasma versus standard care as treatment for severe and/or critical COVID-19 (as defined in the inclusion criteria) in adults 18 years of age and older. A total of 350 eligible subjects will receive a transfusion of anti-SARS-CoV2 ( severe acute respiratory syndrome) convalescent plasma.
Primary Outcome
Total number of grade 3 and above throughout study period
Interventions
- BIOLOGICAL COVID 19 Convalescent Plasma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2020-03-20 |
| Est. Completion | 2023-12-20 |
| Phase | Phase 1 |
What the finished NCT04554992 record still lists
NCT04554992 is an interventional study that assigns participants to a tested intervention. The registered 350 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (483% higher).
The record links to 0 conditions, and to 1 intervention - of which COVID 19 Convalescent Plasma is the first listed.
NCT04554992 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04554992 about?
NCT04554992 is a clinical study titled "Convalescent Plasma for the Treatment of COVID-19 (Coronavirus Disease 2019)". This pilot, prospective study will assess the safety and efficacy of COVID-19 convalescent plasma versus standard care as treatment for severe and/or critical COVID-19 (as defined in the inclusion criteria) in adults 18 years of age and older. A total of 350 eligible subjects will receive a transfus...
What is the current status of trial NCT04554992?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 350 participants. The study started on 2020-03-20. Estimated completion is 2023-12-20.
What interventions are being tested in trial NCT04554992?
The interventions under investigation include: COVID 19 Convalescent Plasma (BIOLOGICAL).
Who is sponsoring clinical trial NCT04554992?
This trial is sponsored by The Methodist Hospital Research Institute, which has 126 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04554992's enrollment target sits among peer trials
350 97th of 2000 higher than 1,902 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00900575 · 350 participants · NA
Cervical Cancer Detection Using Optical Spectroscopy
- NCT01627821 · 350 participants · NA
Evaluation of the Jarvik 2000 Left Ventricular Assist System With Post-Auricular Connector--Destination Therapy Study
- NCT02357654 · 350 participants · Phase 4
GnRH for Luteal Support in IVF/ICSI/FET Cycles
- NCT03997370 · 350 participants · Phase 1
Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI